Despite advances in proteasome inhibitors (such as BTZ) and chimeric antigen receptor (CAR) T-cell therapies, MM remains incurable due to drug resistance and toxicity [23,24,25]. This evidence concerns the gene CASC3 and Miyoshi myopathy.